Renowned microbiologist will bring clinical expertise as the company advances its platform for rapid pathogen identification and antibiotic susceptibility testing AUSTIN, Texas — March 10, 2022 — Pattern Bioscience, Inc., developer of Digital Culture™ technology for...
AUSTIN, Texas, December 8, 2021 – Pattern Bioscience, Inc. has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Pneumonia Action Panel. The test uses Pattern’s Digital CultureTM technology to provide a fast and...
Pattern recently interviewed Cindy Lopez, Director of People and Culture, about building a great place to work—both during these challenging times and beyond. Let’s start by giving everyone a little background info on your professional journey. I started with a...
Led by Illumina Ventures, the Series B-1 round will accelerate development and validation of transformational bacterial testing technology AUSTIN, Texas, July 14, 2020 – Pattern Bioscience, Inc. today announced $9M in additional funding to accelerate the development...
$6.8M CARB-X award plus $6.4M Series B led by Omnimed will help bring new technology to the fight against drug resistance. AUSTIN, Texas, February 4, 2020 – Pattern Bioscience, Inc., formerly operating as Klaris Diagnostics, today announced $13M in funding for the...
